ERBB2 and breast cancer: However, approximately 50%–60% of HER2‐negative metastatic BC expressed low levels of HER2 [immunohistochemical (IHC) 1+/2+ and negative results on in situ hybridization (ISH)]12, 13 and were defined as HER2‐low BC.